Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jay Dolitsky

Pediatric Otolaryngology New York, NY Medical Doctor

NPI 1649219783 CMS profile 74597

261 5Th Ave Rm 901, New York, NY 10016

Open in the dashboard

General payments

$3,050

129 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jay Dolitsky of New York, NY is reported in the CMS Open Payments database as having received $3,050 across 129 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Pediatric Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $607 24
2024 General $499 15
2023 General $483 21
2022 General $579 19
2021 General $216 10
2020 General $421 25
2019 General $247 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jay Dolitsky
  • Pediatric Otolaryngology median
  • Middle half of Pediatric Otolaryngology
  • National median

In program year 2025, general payments to Jay Dolitsky were reported at $607. Among 368 Pediatric Otolaryngology profiles paid that year, the median was $172 and the middle half received between $78 and $412.

Show as a table
Year Jay Dolitsky Pediatric Otolaryngology median Middle half National median
2019 $247 $127 $51–$271 $163
2020 $421 $64 $31–$165 $114
2021 $216 $88 $26–$225 $132
2022 $579 $122 $43–$316 $149
2023 $483 $128 $52–$340 $160
2024 $499 $150 $65–$384 $164
2025 $607 $172 $78–$412 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. kaleo, Inc. $538 25 payments
  2. GlaxoSmithKline, LLC. $459 16 payments
  3. Genzyme Corporation $305 14 payments
  4. OptiNose US, Inc. $274 20 payments
  5. Novartis Pharmaceuticals Corporation $173 6 payments
  6. Regeneron Healthcare Solutions, Inc. $141 6 payments
  7. Neurent Medical Limited $123 2 payments
  8. Stryker Corporation $116 1 payment
  9. Aerin Medical Inc. $107 2 payments
  10. Medtronic, Inc. $99 3 payments
  11. Other $716 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,050 129 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $438 20 payments
  2. AUVI-Q Allergy $371 18 payments
  3. NUCALA $280 9 payments
  4. Xhance $274 20 payments
  5. AUVI-Q Allergy $167 7 payments
  6. DUPIXENT Inflammation And Immunology $141 6 payments
  7. NEUROMARK Device $123 2 payments
  8. NEUROMARK Radiofrequency Console $123 2 payments
  9. CLARIFIX CRYOTHERAPY DEVICE $116 1 payment
  10. AUDION ET DILATION SYSTEM $116 1 payment
  11. Other $1,704 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

129 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Otolaryngology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record